Now that the Supreme Court has upheld the healthcare reform law, many in the pharmaceutical sector see the path ahead as straightforward. However, simply preparing for those components of the law that directly affect manufacturers won’t be the only challenge. Payers recognize that they have to slow the growth of healthcare costs — and their actions will have profound implications for pharmaceutical and medical device companies. Regulatory approval, physician preference, and patient demand will no longer justify premium pricing for new products.